12 October 2020

Highlights in Medicinal Chemistry IV

Organised by:

SCI's Fine Chemicals Group

Online Webinar - 15:00 - 17:00 BST

Registration Closed

This event is no longer available for registration.

Synopsis

This meeting aims to showcase vignettes of modern medicinal chemistry to bring new thinking to the subject, challenge perceptions and encourage scientific interaction between researchers. The short presentation format of the meeting also aims to provide a focussed forum to promote examples of medicinal chemistry excellence.

 With the current challenges of meeting face to face, this conference has moved to a virtual format. We have three leading speakers in the field of medicinal chemistry covering a diverse range of topics;

 Key learning objectives for the meeting are to:

  • Find out what the future of medicinal chemistry holds - What does v3.0 look like?
  • Gain insights into how to design a small molecule protein degrader
  • Learn about drug design strategies for the inhibition of protein-protein interactions

 In addition to the talks, we will host an interactive, panel discussion with our three key opinion leaders on the future direction of medicinal chemistry where the audience will have the opportunity to participate.

 We look forward to virtually welcoming you to what we hope will be an informative and interactive virtual meeting


Speakers

Dr Mark Bunnage

Vertex

Dr. Bunnage joined Vertex in 2016 as Senior Vice President and Site Head for Boston Research. His team works on a number of serious diseases, including alpha-1 antitrypsin deficiency, focal segmental glomerulosclerosis, and sickle cell disease. Prior to joining Vertex, Dr. Bunnage spent 20 years at Pfizer where he held a variety of roles within Medicinal Chemistry. Dr. Bunnage has broad interests in Drug Discovery and is an author or inventor on over 50 publications and patents. He is a Fellow of the Royal Society of Chemistry and a visiting Professor in Chemistry at the University of Oxford.

Rhian Holvey

Dr Rhian Holvey

Astex

astex pharmaceuticals logo

Rhian Holvey completed her Masters at the University of Oxford in 2009 before moving to the University of Cambridge for the CRUK PhD Training Programme in Chemical Biology and Molecular Medicine, where she was supervised by Professor Chris Abell, Dr Murray Stewart and Professor David Neal. Since 2014 she has been a medicinal chemist at Astex Pharmaceuticals specialising in FBDD with a focus on oncology and neurodegeneration.

Dr William Farnaby

William Farnaby is currently a team leader in medicinal chemistry and chemical biology at the School of Life Sciences, University of Dundee. He leads a multi-disciplinary team of drug discovery scientists engaged in a collaboration between Professor Alessio Ciulli and Boehringer Ingelheim. This unique collaboration model aims to discover bi-valent degraders to address areas of critical unmet medical need. William has led and progressed protein degradation projects through multiple stages of the drug discovery process and in doing so continues to contribute significantly to the advance of rational degrader design, synthesis and methods of biochemical and cellular evaluation. Prior to this William worked for 8 years at Takeda Cambridge as a senior medicinal chemist, contributing to the discovery of a number of pre-clinical and clinical candidates and leading collaborative programs for the discovery of novel CNS focussed chemistries.


Programme
15.00

Welcome and introduction 

15.05
Key aspects of structure-based drug design strategies from the development of a potent class of small molecule inhibitors of the MDM2-p53 protein-protein interaction 
Dr Rhian Holvey,  Astex 

15.35
Structure based and empirical approaches for small molecule degrader design 
Dr William Farnaby, University of Dundee
16.05
Medicinal Chemistry 3.0
Dr Mark Bunnage, Vertex
16.40
Panel session: What should the Medicinal Chemistry discipline be like in 10 years?
Hosted by Al Dossetter, Medchemica


14.30
First Speaker
Dr Antony Williams, Cheminformatician, US Environmental Protection Agency (EPA)
15.15
Break
15.20
Q&A session

Fees
Introductory Prices available until 2nd October:
Non-Members: £50.00
SCI Members: £25.00
Students: £10.00 

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations


Booking Process/Deadlines

Booking terms and conditions


 


Sponsors

Sponsorship

For further information and prices, please email conferences@soci.org. Spaces are limited and will be allocated on a first come, first served basis.


Organising Committee
  • Jo Pinder, Vertex Ltd, UK
  • Jamie Scott, SCI/ AstraZeneca
  • Al Dossetter, SCI/ MedChemica Limited
  • Nigel Swain, SCI/ Heptares Therapeutics


 Conference Team

Email: conferences@soci.org
Tel: +44 (0)20 7598 1561